At a time when life sciences companies have seen an unprecedented acceleration in the adoption of digital tools, many are now faced with managing a myriad of tools and applications with varying levels of security and technology requirements. Biopharma and medical device manufacturers are now exploring solutions and platforms that can provide the stability, regulatory compliance, and end-to-end connectivity needed to design, deliver and scale digital solutions that deliver clinical and economic benefits to patients, providers and payers. In this session, Brian Williams, Chief Digital Officer for Life Sciences at Cognizant, will discuss the opportunity available to digital-first companies that are considering cloud platforms like Philips HealthSuite, which is built on Amazon Web Services.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
